Finn
NVS Pharmaceuticals · Large pharma · Innovative medicines · Specialty drugs · Thesis updated November 1, 2026

Novartis raises guidance as new drugs offset pipeline setbacks

01 Running thesis

Execution meets pipeline failure

The bull case centers on excellent commercial execution. Novartis raised its full-year 2026 guidance following a strong third quarter, driven by Kisqali in early breast cancer and the launch of Rhapsido. The company even pushed its peak sales target for Rhapsido beyond USD 4 billion.

However, the long-term pipeline just took a major hit. The highly anticipated Avidity asset del-zota failed its Phase 3 trial, forcing Novartis to take a USD 1.9 billion impairment charge. Another late-stage drug, pelacarsen, also failed its Phase 3 study. This puts more pressure on current products to maintain growth.

On top of pipeline misses, policy risk remains high. Novartis agreed in December 2025 to launch future medicines with comparable prices across high-income countries. CMS also picked Cosentyx, Kisqali, and Xolair for Medicare price negotiation for 2028.

Finn lands near the middle because both sides are very real. Novartis is squeezing more profit out of its current portfolio, hitting a 41.6% core margin. Yet investors are paying for a company that must navigate price caps and clinical failures to keep growing.

Oct 2026→Novartis delivered strong Q3 execution and raised guidance, but the Avidity asset del-zota and pelacarsen both failed Phase 3 trials, leading to a USD 1.9 billion impairment.
Jul 2026▲Novartis returned to top-line growth in Q2 2026, and Kisqali crossed USD 1 billion in quarterly United States sales, demonstrating strong commercial execution.
Feb 2026▼The risk view worsened after Novartis disclosed a December 2025 United States pricing agreement and CMS selection of Cosentyx, Kisqali, and Xolair for 2028 Medicare negotiation.
Feb 2026▲The execution view improved because Novartis hit a 40.1% core margin in 2025, two years ahead of plan, while Kisqali, Pluvicto, Kesimpta, and Scemblix all grew strongly.
Oct 2025→The Avidity deal improved the long-term pipeline with assets expected to avoid IRA impact, but it also added 1 to 2 points of core margin dilution for the next several years.
Jul 2025▲Q2 2025 showed strong Pluvicto pre-taxane launch progress and strong Kisqali early breast cancer uptake, partly offset by Cosentyx and China concerns.
Apr 2025▲Q1 2025 showed margin strength and important approvals for Pluvicto, Vanrafia, and Fabhalta. Management also outlined a USD 23 billion United States manufacturing plan.
Jan 2025▲Kisqali patent protection was clarified until at least Q1 2031, reducing a near-term generic worry. Pipeline updates in neuroscience and rare disease also helped.
02 Business model

Patents, launches, and discipline

Novartis makes money by discovering, buying, testing, manufacturing, and selling patented drugs. The company focuses on specialty areas with high unmet needs instead of crowded mass markets where rebates can eat into prices.

The current plan targets more than 5% average annual sales growth through 2028. Management is trying to reach that by scaling drugs such as Kisqali, Kesimpta, Pluvicto, Scemblix, and Rhapsido. Strong sales helped the company reach a 41.6% core operating margin in the third quarter of 2026.

The model breaks when patents expire, policy limits pricing, or clinical trials fail. Generic copies have already hurt older drugs. The recent Phase 3 failures of del-zota and pelacarsen show the high risk of relying on acquired pipeline assets to replace expiring patents.

Novartis is also spending heavily to reduce supply chain risk. Management is investing USD 23 billion with a goal of making 100% of key United States products end-to-end inside the country.

03 Product portfolio

The drugs that matter

Cash cow

Cosentyx

Cosentyx is a major immunology drug with USD 6.7 billion of 2025 sales. It is still important, but Medicare price negotiation for 2028 is a clear risk.

Growth engine

Kisqali

Kisqali is a breast cancer drug and one of Novartis's biggest growth engines. It recently crossed USD 1 billion in quarterly United States sales.

Growth engine

Kesimpta

Kesimpta treats multiple sclerosis. It reached USD 4.4 billion of 2025 sales and continues to grow strongly.

Growth engine

Pluvicto

Pluvicto is a radioligand therapy for prostate cancer. It uses a targeted radioactive payload to attack cancer cells and is expanding into earlier treatment settings.

Growth engine

Scemblix

Scemblix treats chronic myeloid leukemia. The company expects it to reach front-line leadership in the United States in late 2026.

Steady

Entresto

Entresto remains important in heart failure, but it is now a managed decline story in the United States. The drug accepted a maximum fair price under the IRA for 2026, and generics entered the market in mid-2025.

Growth engine

Rhapsido

Rhapsido is an oral BTK inhibitor for chronic spontaneous urticaria. Management recently upgraded its peak sales guidance to over USD 4 billion.

04 Business segments

Where sales come from

United States43%growing fast
Europe31%modest
Emerging growth markets26%modest

The mix uses 2025 net sales from continuing operations in the Form 20-F. Novartis reports as one innovative medicines company, making these geographic sales buckets rather than separate profit segments.

05 Risk factors

What could go wrong

United States drug price cuts

High impact · High odds

Cosentyx, Kisqali, and Xolair were selected for Medicare price negotiation for 2028. Entresto already accepted a maximum fair price for 2026. If negotiated prices are harsh, growth drugs could be worth less than investors expect.

We watchCMS final negotiated prices for Cosentyx, Kisqali, and Xolair for 2028.

Pipeline execution failures

High impact · Medium odds

Novartis took a USD 1.9 billion impairment charge in the third quarter of 2026 after its Avidity asset del-zota failed a Phase 3 trial. Pelacarsen also failed its Phase 3 study, wiping out expected future revenues.

We watchClinical readouts and FDA action dates for remaining assets like remibrutinib and ianalumab.

Generic erosion in 2026

Medium impact · High odds

United States generics for Entresto, Promacta, and Tasigna entered the market in mid-2025. Older products continue to drag on the newer portfolio.

We watchQuarterly sales growth for Entresto, Promacta, Tasigna, and total company sales.

Global launch price cap

High impact · Medium odds

Novartis agreed with the United States administration to launch future medicines with comparable prices across high-income countries. That could limit the old playbook of charging much higher prices for new drugs.

We watchNet price and gross-to-net trends for major new launches after the December 2025 agreement.
06 Quick answers

In one breath

What does Novartis do?

Novartis develops and sells patented medicines. Its main focus areas are cardiovascular, renal and metabolic disease, immunology, neuroscience, and oncology.

Why did Novartis take a USD 1.9 billion impairment?

The Avidity asset del-zota failed its Phase 3 HARBOR trial. This forced the company to write down its value and delay launch timelines.

What are the biggest Novartis growth drugs?

Kisqali, Kesimpta, Pluvicto, Scemblix, and Rhapsido are the clearest current growth drivers. Kisqali and Rhapsido have shown especially strong momentum recently.

Why is Novartis stock not scored higher?

The company is executing well, but the price and pipeline risks are real. Key drugs face United States Medicare price negotiation, and recent Phase 3 clinical failures hurt the long-term outlook.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Novartis 2025 Form 20-F
  2. Novartis Q3 2026 earnings transcript
  3. Novartis Q2 2026 earnings transcript
08 Explore the industry

Comparable Drug Manufacturers - General companies

Companies near Novartis AG in Finn's Drug Manufacturers - General industry ranking.

Get started with Finn today